Reporting of Conflicts of Interest in Meta-Analyses of Trials of Pharmacological Treatments

Roseman, Michelle; Milette, Katherine; Bero, Lisa; Coyne, James C.; Lexchin, Joel; Turner, Erick H.; Thombs, Brett D.

doi:10.1097/01.sa.0000407039.12987.34

Cited by 19 publications

(30 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Discrepancies were resolved by consensus. Risk of bias in studies included for both review questions was assessed with the Cochrane Risk of Bias tool [27] (see Appendix F), including assessment of financial conflicts of interest as has been recommended [28,29]. Risk of bias was assessed by two investigators, with discrepancies resolved by consensus.…”

Section: Evaluation Of Eligible Studiesmentioning

confidence: 99%

Effects of screening for psychological distress on patient outcomes in cancer: A systematic review

Meijer

Roseman

Delisle

et al. 2013

Journal of Psychosomatic Research

Self Cite

117

View full text Add to dashboard Cite

Section: Evaluation Of Eligible Studiesmentioning

confidence: 99%

Effects of screening for psychological distress on patient outcomes in cancer: A systematic review

Meijer

Roseman

Delisle

et al. 2013

Journal of Psychosomatic Research

Self Cite

117

View full text Add to dashboard Cite

“…В мета-анализах, опубликованных в журналах с высоким индексом цитирования, редко публикуется кон-фликт интересов [25]. Эта проблема существует и в Кокрейновских анализах.…”

Section: мета-анализы исследований и систематические обзорыunclassified

Drugs Efficiency and Safety: The Role of Pharmaceutical Industry

Belyalov

2015

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Иркутская государственная медицинская академия последипломного образования 664049, Иркутск, микрорайон Юбилейный, 100Проанализированы связи фармацевтической индустрии с медицинской наукой и практикой. Рассмотрены вопросы влияния фармацевтических компаний на иссле-дования лекарственных препаратов, на публикации результатов исследований, на государственные контролирующие органы, врачей и научных работников. Relationships of pharmaceutical industry with medical science and practice are analyzed. The influence of pharmaceutical industry on clinical trials, journal publications, governmental organizations, physicians and researchers is discussed.

show abstract

“…In metaanalyses of antihypertensive drugs, financial ties to a pharmaceutical company were not associated with favourable results, but were linked to four times higher odds to report favourable conclusions 20 . Furthermore, conflict of interests in the original studies included in meta-analyses are usually silenced and unreported 21 . For example, a recent study revealed that only 2 of 29 pharmacological metaanalyses reported the funding sources of the trials and none of them reported author-industry ties in the primary trials 21 .…”

Section: How the Industry Influences Healthcare Research Strategy Ementioning

confidence: 99%

Undue influences on drugs and device industries distort healthcare research, and practice

Rahman¹,

Farzana

2015

Bangladesh J Bioethics

View full text Add to dashboard Cite

Background: Expenditure on industry products (mostly drugs and devices) has spiraled over the last 15 years and accounts for substantial part of healthcare expenditure. The enormous financial interests involved in the development and marketing of drugs and devices may have given excessive power to these industries to influence medical research, policy, and practice. Material and methods: Review of the literature and analysis of the multiple pathways through which the industry has directly or indirectly infiltrated the broader healthcare systems. We present the analysis of the industry influences at the following levels: (i) evidence base production, (ii) evidence synthesis, (iii) understanding of safety and harms issues, (iv) cost-effectiveness evaluation, (v) clinical practice guidelines formation, (vi) healthcare professional education, (vii) healthcare practice, (viii) healthcare consumer's decisions. Results: We located abundance of consistent evidence demonstrating that the industry has created means to intervene in all steps of the processes that determine healthcare research, strategy, expenditure, practice and education. As a result of these interferences, the benefits of drugs and other products are often exaggerated and their potential harms are downplayed, and clinical guidelines, medical practice, and healthcare expenditure decisions are biased. Conclusion: To serve its interests, the industry masterfully influences evidence base production, evidence synthesis, understanding of harms issues, cost-effectiveness evaluations, clinical practice guidelines and Healthcare professional education and also exerts direct influences on professional decisions and health consumers. There is an urgent need for regulation and other action towards redefining the mission of medicine towards a more objective and patient-, population-and society-benefit direction that is free from conflict of interests.

show abstract

Reporting of Conflicts of Interest in Meta-Analyses of Trials of Pharmacological Treatments

Cited by 19 publications

References 44 publications

Effects of screening for psychological distress on patient outcomes in cancer: A systematic review

Effects of screening for psychological distress on patient outcomes in cancer: A systematic review

Drugs Efficiency and Safety: The Role of Pharmaceutical Industry

Undue influences on drugs and device industries distort healthcare research, and practice

Contact Info

Product

Resources

About